CLYMClimb Bio, Inc.Healthcare · Biotechnologyas of 2026-09-25
Horizon

Issued 2026-09-25 at $11.66 · now $11.66 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, CLYM has typically landed between $8.08 and $17.22 — a range of −30.7% to +47.7% from the issuance price $11.66.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

493 overlapping 1 month windows · 2024-09-09 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($11.66) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where CLYM has typically landed a month from the 2026-09-25 close of $11.66 — the range is history, not a prediction.

$8.08worst · -30.7%$17.22best · +47.7%
  • now $11.66 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $11.75 (+0.8%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $9.61–$13.9
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $8.08–$17.22
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 493 windows spanning 2024-09-09 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-11-29−44.3%−44.3%+0.9%
2024-09-20−43.1%−43.1%+0.0%
2024-11-27−42.5%−42.5%+1.2%
3 best
2025-11-20+183.2%−5.2%+183.2%
2025-11-24+175.6%−6.8%+178.4%
2025-11-25+173.9%−8.9%+173.9%

493 overlapping windows · 2024-09-09 – 2026-09-25 · not cherry-picked

Pending catalysts

  • August 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) (source, as of 2026-08-14)
  • September 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) (source, as of 2026-08-14)
  • October 2027 — Trial primary completion: Phase 2 primary completion: A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~2 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
100%
+8.7%
n=2
Feb
50%
+18.1%
n=2
Mar
0%
−10.0%
n=2
Apr
100%
+19.7%
n=2
May
50%
+5.7%
n=2
Jun
100%
+12.0%
n=2
Jul
50%
+2.1%
n=2
Aug
100%
+37.3%
n=2
Sep
0%
−12.5%
n=2
Oct
50%
−11.4%
n=2
Nov
0%
−11.7%
n=2
Dec
50%
+33.7%
n=2

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$18$22026-09-15: 1 insider sale, $1.4M — Thomas Stephen Basil2026-06-29: 1 insider sale, $407K — Brennan Aoife2026-02-26: 1 insider sale, $114K — Thomas Stephen Basil2026-02-25: 1 insider sale, $236K — Thomas Stephen Basil2026-02-13: 1 insider sale, $58K — Thomas Stephen Basil2026-02-12: 1 insider sale, $471K — Thomas Stephen Basil2026-01-05: 1 insider purchase, $25K — RA CAPITAL MANAGEMENT, L.P.2025-12-12: 1 insider purchase, $290K — RA CAPITAL MANAGEMENT, L.P.2025-12-11: 1 insider purchase, $465K — RA CAPITAL MANAGEMENT, L.P.2025-12: 2 open-market purchases, $755K2026-01: 1 open-market purchase, $25K2026-02: 4 open-market sales, $879K2026-06: 1 open-market sale, $407K2026-09: 1 open-market sale, $1.4M↑ buys↓ salesdirector Thomas Stephen Basil — Sale on 2026-09-15, filed 2 days after the tradedirector Brennan Aoife — Sale on 2026-06-29, filed 1 day after the tradedirector Thomas Stephen Basil — Sale on 2026-02-26, filed 1 day after the tradedirector Thomas Stephen Basil — Sale on 2026-02-25, filed 2 days after the tradedirector Thomas Stephen Basil — Sale on 2026-02-13, filed 4 days after the tradedirector Thomas Stephen Basil — Sale on 2026-02-12, filed 5 days after the tradedirector RA CAPITAL MANAGEMENT, L.P. — Purchase on 2026-01-05, filed 2 days after the tradedirector RA CAPITAL MANAGEMENT, L.P. — Purchase on 2025-12-12, filed 3 days after the tradedirector RA CAPITAL MANAGEMENT, L.P. — Purchase on 2025-12-11, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-09-15Thomas Stephen BasildirectorSale100,000 @ $13.67$1.4M−17.6% of holdingnot yet — horizon still opennot yet — horizon still open467,969Form 4 · filed 2 days after the trade
2026-06-29Brennan AoifedirectorSale30,902 @ $13.17$407K−26.0% of holding−7.8%not yet — horizon still open87,731Form 4 · filed 1 day after the trade
2026-02-26Thomas Stephen BasildirectorSale16,313 @ $7.01$114K−9.5% of holding+2.9%+91.6%154,657Form 4 · filed 1 day after the trade
2026-02-25Thomas Stephen BasildirectorSale33,687 @ $7.00$236K−16.5% of holding+7.0%+115.7%170,970Form 4 · filed 2 days after the trade
2026-02-13Thomas Stephen BasildirectorSale10,000 @ $5.81$58K−4.7% of holding+27.2%+193.6%204,657Form 4 · filed 4 days after the trade
2026-02-12Thomas Stephen BasildirectorSale90,000 @ $5.23$471K−29.5% of holding+37.1%+195.3%214,657Form 4 · filed 5 days after the trade
2026-01-05RA CAPITAL MANAGEMENT, L.P.directorPurchase7,111 @ $3.50$25K+0.2% of holding+42.9%+274.4%3,403,429Form 4 · filed 2 days after the trade
2025-12-12RA CAPITAL MANAGEMENT, L.P.directorPurchase101,462 @ $2.86$290K+3.1% of holding+30.4%+246.3%3,396,318Form 4 · filed 3 days after the trade
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorPurchase213,099 @ $2.18$465K+6.9% of holding+78.6%+389.4%3,294,856Form 4 · filed 4 days after the trade
2025-06-30Brennan AoifedirectorSale20,618 @ $1.22$25K−30.0% of holding+19.9%+246.1%48,132Form 4 · filed 1 day after the trade
2025-06-20Pimblett EmilyofficerSale1,242 @ $1.24$2K−6.2% of holding+10.7%+247.8%18,888Form 4 · filed same day
2025-03-20Pimblett EmilyofficerSale1,199 @ $1.31$2K−7.3% of holding+4.9%+62.1%15,130Form 4 · filed same day
2024-12-19Pimblett EmilyofficerSale1,235 @ $2.02$2K−9.8% of holding−11.1%−37.9%11,329Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

61 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-29Celebi Breanna MaurinedirectorAward / grant70,28470,284Form 4
2026-06-29RA CAPITAL MANAGEMENT, L.P.directorAward / grant70,28470,284Form 4
2026-06-27Brennan AoifedirectorOption exercise68,750137,500Form 4
2026-06-27Brennan AoifedirectorOption exercise68,750118,633Form 4
2026-06-27Brennan AoifedirectorOption exercise68,750118,633Form 4
2026-06-05Thomas Stephen BasildirectorAward / grant40,00040,000Form 4
2026-06-05Cumbo AlexanderdirectorAward / grant40,00040,000Form 4
2026-06-05WILLIAMS DOUGLAS EdirectorAward / grant40,00040,000Form 4
2026-06-05Drapkin Kimberlee CdirectorAward / grant40,00040,000Form 4
2026-06-05Levin Andrew DaviddirectorAward / grant40,00040,000Form 4
2026-06-05RA CAPITAL MANAGEMENT, L.P.directorAward / grant40,00040,000Form 4
2026-06-05Dunn JudithdirectorAward / grant40,00040,000Form 4
2026-04-29RA CAPITAL MANAGEMENT, L.P.directorAward / grant2,106,00022,546,000Form 4
2026-01-06ALTSCHULLER SusandirectorAward / grant142,500142,500Form 4
2026-01-06Wilson Perrin MeganofficerAward / grant300,000300,000Form 4
2026-01-06Driscoll CindyofficerAward / grant100,000100,000Form 4
2026-01-06Brennan AoifedirectorAward / grant700,000700,000Form 4
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorDisposition20,440,0003,081,757Form 4
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorAward / grant20,440,00020,440,000Form 4
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorAward / grant20,440,00020,440,000Form 4
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorAward / grant20,440,00020,440,000Form 4
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorAward / grant20,440,00020,440,000Form 4
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorAward / grant20,440,00020,440,000Form 4
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorAward / grant20,440,00020,440,000Form 4
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorAward / grant20,440,00020,440,000Form 4
2025-12-11RA CAPITAL MANAGEMENT, L.P.directorAward / grant20,440,00020,440,000Form 4
2025-10-01ALTSCHULLER SusandirectorAward / grant600,000600,000Form 4
2025-08-07Thomas Stephen BasildirectorAward / grant100,375304,657Form 4
2025-06-27Thomas Stephen BasildirectorOption exercise25,0940Form 4
2025-06-27Brennan AoifedirectorOption exercise68,750206,250Form 4
2025-06-27Brennan AoifedirectorOption exercise68,75068,750Form 4
2025-06-27Thomas Stephen BasildirectorOption exercise25,094204,282Form 4
2025-06-18Pimblett EmilyofficerOption exercise5,00015,000Form 4
2025-06-18Pimblett EmilyofficerOption exercise5,00020,130Form 4
2025-06-17Driscoll CindyofficerAward / grant200,000200,000Form 4
2025-06-04Levin Andrew DaviddirectorAward / grant40,00040,000Form 4
2025-06-04Cumbo AlexanderdirectorAward / grant40,00040,000Form 4
2025-06-04Thomas Stephen BasildirectorAward / grant40,00040,000Form 4
2025-06-04WILLIAMS DOUGLAS EdirectorAward / grant40,00040,000Form 4
2025-06-04Dunn JudithdirectorAward / grant40,00040,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.